Article Text

Download PDFPDF
Letter
Unified definition of relapse-free survival should be used for evaluating survival benefit in oesophageal adenocarcinoma
  1. Weizheng Li
  1. Department of Gastroenterology, Maoming People’s Hospital, Maoming 525000, China
  1. Correspondence to Dr Weizheng Li, Department of Gastroenterology, Maoming People’s Hospital, Maoming 525000, China; lee_weizheng{at}163.com

Statistics from Altmetric.com

With great interest, I read the report1 by Turkington et al and applaud their proposed DNA damage immune response (DDIR) assay, which could predict survival benefit from DNA-damaging neoadjuvant chemotherapy following surgical resection in oesophageal adenocarcinoma (OAC). However, the definition of relapse-free survival (RFS) in their study was not widely accepted, leading to poor comparability among studies.

In the present study, RFS was defined as …

View Full Text

Footnotes

  • Contributors The manuscript was written by WL.

  • Funding The work is supported by High-level Hospital Construction Research Project of Maoming People’s Hospital.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.